Parkinson Disease
Conditions
Keywords
Parkinson's, Lithium, Free water, Disease-modifying therapy
Brief summary
This study will examine the effects of lithium 20mg/day compared to placebo on MRI and blood-based biomarkers among 20 early-stage Parkinson's disease patients.
Detailed description
In observational studies, small daily doses of lithium have been associated with a 77% reduced risk of developing Parkinson's disease (PD). In addition, lithium therapy has been effective in preventing neuronal death and behavioral symptoms in several PD animal models. Recently, our group has shown 24-weeks of low-dose lithium therapy in PD to improve both MRI and blood-based biomarkers implying that lithium may be slowing the progression of the disease. However, these findings stem from only three of four patients receiving MRIs. A larger study will be required to determine if these promising results can be replicated. The proposed study will enroll 20 additional PD patients who will be randomly assigned to receive either lithium 20mg/day or identically-appearing placebo capsules for 24 weeks. This will be a double-blind study meaning that neither the patients nor the study team will know to which therapy patients have been assigned. Positive results from this study will support further research on lithium that could eventually support lithium as a disease-modifying therapy for PD that could improve patients' long-term prognoses.
Interventions
DIETARY_SUPPLEMENTLithium
5mg of elemental lithium/capsule
OTHERPlacebo
Cellulose-filled capsules
Sponsors
State University of New York at Buffalo
Cure Parkinson's
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Double-blind, placebo-controlled
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Have PD for \<4 years diagnosed by a movement disorder specialist. Have normal thyroid and renal function at the screening visit. Have no previous exposure to lithium therapy. Have no history of brain surgery. Have no hx of brain imaging findings suggesting another neurological condition besides PD. Have no use of tobacco or THC products for \>1 year. Have stable PD medications for \>30 days without current need for adjustments in the investigator's opinion. Have stable psychiatric and diuretic medications for \>60 days with no anticipated need for changes for at least 24 weeks. Have no active medical or psychiatric condition that may interfere with study procedures in the investigator's opinion.
Exclusion criteria
* Have PD for \>4 years or does not have PD. Have abnormal normal thyroid and renal function at the screening visit. Have previous exposure to lithium therapy. Have history of brain surgery. Have hx of brain imaging findings suggesting another neurological condition besides PD. Have use of tobacco or THC products within the past year. Have PD medication adjustments within 30 days or needs PD medication adjustments in the investigator's opinion. Have psychiatric or diuretic medication adjustments within the last 60 days or is anticipated to need changes over next 24 weeks. Have active medical or psychiatric condition that may interfere with study procedures in the investigator's opinion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MRI-derived free water (FW) levels. | Change from baseline (BL) to 24 week | FW in the posterior substantia nigra (pSN), dorsomedial nucleus of the thalamus (DMN-T) and the nucleus basalts of Meynert (nbM). |
| Peripheral blood mononuclear cell (PBMC) nuclear receptor-related 1 protein (Nurr1) mRNA expression | Change from baseline (BL) to 24 week | PBMC Nurr1 mRNA expression using Taqman PCR. |
| Serum neurofilament light chain (NfL) | Change from baseline (BL) to 24 week | Serum NfL assessed using SIMOA platform by Quanterix (Lexington, MA) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PBMC superoxide dismutase type-1 (SOD-1) mRNA expression | Change from baseline (BL) to 24 week | PBMC SOD-1 mRNA expression using Taqman PCR |
| PBMC pS9/total glycogen synthase kinase-3B (GSK-3B) ratio | Change from baseline (BL) to 24 week | Assessed using ELISA |
| PBMC pThr308 and pS473/total protein kinase B (Akt) ratios | Change from baseline (BL) to 24 week | Assessed using ELISA |
| Serum interleukin-6 | Change from baseline (BL) to 24 week | Assessed using ELISA |
| Serum glial fibrillary acidic protein (GFAP) | Change from baseline (BL) to 24 week | Serum GFAP assessed using SIMOA platform by Quanterix (Lexington, MA) |
| Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination) | Change from baseline (BL) to 24 week | Assessed in the "on" state. Score range 0-132 with higher scores indicating worse outcomes. |
| Montreal Cognitive Assessment (MoCA) | Change from baseline (BL) to 24 week | Score range 0-30 with higher scores indicating better outcomes. |
| Parkinson's Anxiety Scale | Change from baseline (BL) to 24 week | Score range 0-48 with higher scores indicating worse outcomes. |
| Geriatric Depression Scale-15 | Change from baseline (BL) to 24 week | Score range 0-15 with higher scores indicating worse outcomes. |
| Fatigue Severity Scale | Change from baseline (BL) to 24 week | Score range 9-63 with higher scores indicating worse outcomes. |
| Insomnia Severity Index | Change from baseline (BL) to 24 week | Score range 0-28 with higher scores indicating worse outcomes. |
| Parkinson's Disease Questionnaire-8 | Change from baseline (BL) to 24 week | Score range 0-32 with higher scores indicating worse outcomes. |
| Levodopa equivalent daily dose (LEDD) | Change from baseline (BL) to 24 week | Higher scores indicate higher dose of dopaminergic therapy. |
Countries
United States
Outcome results
None listed